Track topics on Twitter Track topics that are important to you
STUART, FL--(Marketwired - August 10, 2015) - Liberator Medical Holdings, Inc. (NYSE MKT: LBMH) today announced the financial results for its fiscal third quarter ended June 30, 2015.
Net sales for the three months ended June 30, 2015, increased by $1,798,000, or 9.7%, to $20,376,000, compared with net sales of $18,578,000 for the three months ended June 30, 2014. Net sales for the nine months ended June 30, 2015, increased by $5,432,000, or 9.9%, to $60,266,000, compared with net sales of $54,834,000 for the nine months ended June 30, 2014. The increase in net sales was primarily due to our continued emphasis on our direct response advertising campaign to acquire new customers and our emphasis on customer service to maximize the reorder rates for our recurring customer base.
*Litigation settlement expenses for the three months ended June 30, 2015 include a $600,000 accrual associated with the agreement in principal to settle the civil qui tam litigation (see Note 7 to the Consolidated Financial Statements (unaudited) contained in the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2015)
Gross profit for the three months ended June 30, 2015, increased by $709,000, or 6.0%, to $12,460,000, compared with gross profit of $11,751,000 for the three months ended June 30, 2014. For the nine months ended June 30, 2015, gross profit increased by $2,785,000, or 8.1%, to $37,299,000, compared with gross profit of $34,514,000. The increase was attributed to our increased sales volume for the three and nine months ended June 30, 2015, compared with the three and nine months ended June 30, 2014.
Income from operations for the three months ended June 30, 2015, decreased by $759,000, or 24.4%, to $2,357,000, compared with the three months ended June 30, 2014. The decrease in operating income is primarily attributed to increases in litigation settlement costs, advertising, and bad debt expense, partially offset by increased gross profit driven by our increased sales volume and a reduction, as a percentage of sales, in payroll expenses and other general and administration expenses.
The Company received subpoenas from the United States Department of Justice and is a defendant, among other defendants, in a civil qui tam litigation alleging, inter alia, violations of the federal False Claims Act, 31 U.S.C. §3729. United States ex rel. Herman, et al. v. Coloplast A/S, et al., Docket No. 11-cv-12131-RWZ (D. Mass). With the concurrence of all of the other parties to the litigation, the litigation is stayed until September 21, 2015. The Company has fully cooperated with the government's investigation. The Company has recently reached an agreement in principle to fully settle and resolve all claims asserted the litigation. The settlement is subject to final approvals, as well as negotiation and execution of settlement documents. Based upon the agreement in principle, the Company has accrued the expected expenses for the settlement, and a reasonable estimate of these expenses is $600,000, which amount includes the amount payable to the government, as well as the Company's share of the relators' counsel fees and expenses. If the agreement in principle is not consummated, the additional cost, if any, to the Company cannot be reasonably estimated at this time given that the litigation has not proceeded beyond its preliminary stages and that the litigation is currently stayed, and the $600,000 accrual may not be sufficient.
Net income for the third quarter of fiscal year 2015 was $1,669,000, or $0.03 per diluted share, compared with net income of $1,983,000, or $0.03 per diluted share, for the third quarter of fiscal year 2014, a decrease of $314,000 or 15.8%. The decrease in net income is primarily attributed to increases in litigation settlement costs, advertising, and bad debt expense, partially offset by increased gross profit driven by our increased sales volumes and a reduction, as a percentage of sales, in payroll expenses and other general and administration expenses.
The Company had cash of $9,095,000 at June 30, 2015, compared with cash of $12,261,000 at September 30, 2014, a decrease of $3,166,000. The decrease in cash for the nine months ended June 30, 2015, was due to $4,659,000 of cash used in financing activities, $90,000 of cash used in investing activities, partially offset by $1,583,000 of cash provided by operating activities.
Mark Libratore, President and CEO, commented, "I am pleased to report 9.9% year-over-year revenue growth for the nine months ended June 30, 2015. Our efforts to improve the customer experience have delivered just under 15% revenue retention for the three months, and 13% for the nine months ended June 30th
. Creating value for our customers is an essential step in continuing to grow the value of Liberator. I am not pleased with the drop in net income year-over-year. In the absence of one-time expenses our net income would have grown. We are very focused on reducing extraordinary expenses and protecting shareholder value. We will continue creating efficiencies, improving profitability and strengthening our quality and compliance systems as we head into our fiscal forth quarter."
Stay up-to-date with current events by visiting Liberator Medical's website at www.liberatormedical.com or by joining the Company's E-Mail Alert List. Join by clicking the following link www.LBMH-IR.com.
About Liberator Medical Holdings, Inc. Liberator Medical Holdings, Inc.'s subsidiary, Liberator Medical Supply, Inc., established the Liberator brand as a leading national direct-to-consumer provider of quality medical supplies to Medicare-eligible seniors. Accredited by The Joint Commission, our Company's unique combination of marketing, industry expertise and customer service has demonstrated success over a broad spectrum of chronic conditions. Liberator is recognized for offering a simple, reliable way to purchase medical supplies needed on a regular, ongoing, repeat-order basis, with the convenience of direct billing to Medicare and private insurance. Liberator's revenue primarily comes from supplying products to meet the rapidly growing requirements of general medical supplies, diabetes supplies, catheters, ostomy supplies and mastectomy fashions . Liberator communicates with patients and their doctors on a regular basis regarding prescriptions and supplies. Customers may purchase by phone, mail or internet, with repeat orders confirmed with the customer and shipped when needed.
Safe Harbor Statement
In this press release and in related comments by our management, our use of the words "expect," "anticipate," "possible," "potential," "target," "believe," "commit," "intend," "continue," "may," "would," "could," "should," "project," "projected," "positioned" or similar expressions is intended to identify forward-looking statements that represent our current judgment about possible future events. We believe these judgments are reasonable, but these statements are not guarantees of any events or financial results, and our actual results may differ materially due to a variety of important factors. Such risks and uncertainties may include, but are not limited to, regulatory limitations on the medical industry in general, working capital constraints, fluctuations in customer demand and commitments, fluctuation in quarterly results, introduction of new services and products, commercial acceptance and viability of new services and products, pricing and competition, reliance upon subcontractors and vendors, the timing of new technology and product introductions, and the risk of early obsolescence of our products. Liberator's most recent annual report on Form 10-K and quarterly reports on Form 10-Q provide information about these and other factors, which we may revise or supplement in future reports filed with the Securities and Exchange Commission.
Liberator Medical Holdings, Inc. and Subsidiaries Condensed Consolidated Balance Sheets As of June 30, 2015 (unaudited) and September 30, 2014
(In thousands, except dollar per share amounts)
See accompanying notes to unaudited condensed consolidated financial statements.
Liberator Medical Holdings, Inc. and Subsidiaries Condensed Consolidated Statements of Operations For the three and nine months ended June 30, 2015 and 2014 (Unaudited)
(In thousands, except per share amounts)
See accompanying notes to unaudited condensed consolidated financial statements.
Liberator Medical Holdings, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows For the nine months ended June 30, 2015 and 2014 (Unaudited)
See accompanying notes to unaudited condensed consolidated financial statementsContacts:Individual Investor Relations ContactWSR Communications772-219-7525 Institutional Investor ContactRobert J. DavisLiberator Medical Holdings, Inc.772-463-3737NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...